Collegium Pharmaceutical Inc (NASDAQ:COLL)’s share price rose 5.5% on Wednesday . The stock traded as high as $21.50 and last traded at $21.13. Approximately 655,800 shares changed hands during mid-day trading, an increase of 40% from the average daily volume of 467,070 shares. The stock had previously closed at $20.02.

COLL has been the subject of several recent research reports. Piper Jaffray Companies set a $23.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, December 14th. Needham & Company LLC lifted their price target on Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. Jefferies Group lifted their price target on Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, November 17th. Finally, Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $23.33.

The stock has a market cap of $685.44 and a PE ratio of -7.06.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The business had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. During the same period in the previous year, the business earned ($1.13) earnings per share. The firm’s revenue was up 2814.6% on a year-over-year basis. sell-side analysts anticipate that Collegium Pharmaceutical Inc will post -2.52 EPS for the current year.

In related news, CEO Michael Thomas Heffernan sold 50,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the transaction, the chief executive officer now directly owns 558,987 shares in the company, valued at $8,681,068.11. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Alison B. Fleming sold 6,928 shares of the business’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $19.07, for a total value of $132,116.96. Following the transaction, the insider now owns 32,651 shares of the company’s stock, valued at $622,654.57. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,065,558 shares of company stock valued at $18,396,477. 25.76% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. boosted its holdings in shares of Collegium Pharmaceutical by 13.5% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 51,119 shares of the specialty pharmaceutical company’s stock worth $944,000 after purchasing an additional 6,083 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Collegium Pharmaceutical by 87.5% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock worth $138,000 after purchasing an additional 3,500 shares in the last quarter. Pura Vida Investments LLC purchased a new position in shares of Collegium Pharmaceutical in the 3rd quarter worth about $1,229,000. Wells Fargo & Company MN boosted its holdings in shares of Collegium Pharmaceutical by 12.8% in the 3rd quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock worth $475,000 after purchasing an additional 5,136 shares in the last quarter. Finally, Citadel Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 773.8% in the 3rd quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock worth $5,707,000 after purchasing an additional 481,771 shares in the last quarter. Institutional investors and hedge funds own 79.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://theolympiareport.com/2018/01/17/collegium-pharmaceutical-coll-stock-price-up-5-5.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.